Loading...
Results of the CRASH-2 trial suggest that tranexamic acid reduces mortality without increasing risk of thrombosis in adult patients with traumatic bleeding (JW Emerg Med Jun 15 2010). In a prespecified analysis of CRASH-2 trial data, researchers assessed whether the effect varies according to baseline risk for death. They stratified 13,273 trauma patients who received placebo or tranexamic acid (1 g over 10 minutes, followed by 1 g over 8 hours) within 3 hours of injury into four groups according to baseline mortality risk: <6%, 6–20%, 21–50%, and >50%.
In each risk group, patients receiving tranexamic acid had significantly fewer fatal and nonfatal thrombotic events and fewer all-cause deaths than those receiving placebo (the mortality bene…